bluuebunny/crossref_metadata_2025_split huggingface dataset:
Real-world evaluation of the treatment yield of implantable loop recorders (ILR) in the Netherlands
Authors: Samuel M , Van Der Stoel M , Van Dijk V , Maass A 
Published: May 2024

Abstract

Background
Implantable loop recorders (ILRs) are invasive and expensive diagnostic tools used to determine the underlying arrhythmias associated with syncope and palpitations as well as capture atrial fibrillation (AF). The diagnostic and treatment yield from ILRs is uncertain. Prior studies indicated that 26-52% ILR patients were diagnosed with arrhythmias and 11-30% received subsequent treatment.

Purpose
Our primary aim was to determine the incidence of pacemaker and ICD implants within 1- and 3- years of ILR implantation. The secondary aims include 1) an evaluation of the incidence of AF ablation, 2) the identification of predictors for treatment, and 3) safety.

Methods
Adult patients who underwent an ILR implant in the Netherlands Heart Registration (NHR) Pacemaker and ICD registry (2018-2021) were included. The NHR device registry was linked to the ablation registry to determine the incidence of AF ablation after ILR. Incidence rates for pacemaker implants, ICD implants, AF ablations, and complications among ILR patients were reported as a proportion of ILR patients over 1- and 3- years. Predictors for treatment following an ILR were determined from multivariable logistic regression models.

Results
From 2018 to 2021, 11,961 patients underwent an ILR implant in the Netherlands. Patients who underwent ILR implantation were a median age 69 (IQR 56-77) years, 46.9% female, and 24.9% had AF. The most frequent indication for ILR implantation was syncope (76.2%), followed by palpitations (15.2%). At 1- and 3-years post-ILR implantation, 12.0% and 14.6% of ILR patients underwent a pacemaker implant, respectively (Figure 1). Fewer patients underwent ICD implants (0.9% and 1.3%) and AF ablation (1.3% and 1.8%) at 1- and 3-years post-ILR implantation, respectively (Figure 1). Compared to males, females were 28% and 70% less likely to undergo a pacemaker and ICD implant following ILR, respectively (Figure 2). Additional predictors for pacemaker implantation included older age, AF, and syncope (p&lt;0.05 for all, Figure 2a). In addition to female sex, AF was a predictor of ICD implantation (Figure 2b). The incidence of complications was relatively low (0.3%). Infection was the most frequent complication (0.2%), followed by device dislocation (0.06%), bleeding (0.02%), and device defect (0.01%).

Conclusion
Despite the benefits of ILRs for long-term remote monitoring, the therapeutic yield of ILRs is relatively low with 14.6%, 1.3%, and 1.8% of ILR patients undergoing implantation for pacemakers, ICDs, and AF ablation at 3-years follow-up. As an expensive and invasive diagnostic tool, a more targeted approach for referrals is warranted to increase the therapeutic yield of the ILRs. Further investigations are warranted to determine the diagnostic yield of ILRs, regardless of subsequent invasive therapy.
Volume-weighted unipolar voltage identifies diffuse fibrosis in patients with non-ischemic cardiomyopathy
Authors: Omara S , Kimura Y , Wijnmaalen A P , Van Der Geest R , Zeppenfeld K 
Published: May 2024

Abstract

Background
Late-gadolinium enhanced cardiac magnetic resonance imaging (LGE-CMR) is currently used to identify non-ischemic scar. However, the distribution of non-ischemic fibrosis related to ventricular arrhythmia (VA) may vary between patients and cannot be accurately delineated by LGE-CMR. Myocardial extracellular volume fraction (ECV) is a promising tool to estimate the amount of diffuse fibrosis in non-ischemic cardiomyopathies (NICM). Novel intra-cardiac mapping derived tools, such as volume-weighted unipolar voltage (vwUV), may allow intraprocedural quantification of diffuse fibrosis.

Purpose
To evaluate the performance of vwUV to determine the segmental amount of non-ischemic fibrosis defined by whole-heart T1 mapping.

Methods
Consecutive patients with a left dominant NICM referred for ablation of VA, who underwent 3D LGE-CMR, whole-heart pre- and post-contrast T1 mapping and high density electroanatomical voltage mapping (EAVM) were included. CMR images were segmented and merged with the 3D EAVM data. The 16-segment AHA model was applied and vwUV and ECVs were determined per segment.

Results
Twenty-one patients (age 54 years [49-60], 18 males [87%], LVEF 47% [37-57%], LGE 7.7% (2.8-18.2%) of LV myocardium) were included and 305 segments analysed. The median ECV per patient was 30.3% (28.8-35.2%). The median segmental vwUV was 1.8mV (1.2-2.3mV). The basal septal and basal inferolateral segments tended to have higher ECV. However there was important variation between patients (figure 1). Of note, the segmental vwUV correlated well with segmental ECV (r = -0.53, p &lt; 0.001) (figure 2).

Conclusions
For the first time, a segmental comparison has been performed between ECV and vwUV. There are important segmental variations of ECV between patients with a NICM referred for VA ablation. The novel intra-cardiac mapping-derived tool of vwUV can localize non-ischemic fibrosis and may facilitate substrate based ablation approaches in this challenging patient population.Figure 1.Segmental ECV valuesFigure 2.Segmental ECV and vwUV
Comparative analysis of pulsed-field and cryoballoon ablation in octogenarians with atrial fibrillation: a multicenter study
Authors: Nakasone K , Della Rocca D G , Magnocavallo M , Betancur A , Pannone L , Mene R , Sorgente A , Sieira J , Almorad A , Stroker E , Sarkozy A , Rossi P , Boveda S , De Asmundis C , Chierchia G B 
Published: May 2024

Abstract

Background
The prevalence of atrial fibrillation (AF) increases with advancing age, and AF contributes to higher rates of stroke, dementia, heart failure, and mortality. Catheter ablation is recognized as an effective treatment for AF; however, data regarding its efficacy in octogenarians are limited. Cryoballoon ablation (CBA) has been reported to be safe and effective in this age group. Recently, single-shot devices using pulsed-field energy have been developed, offering a tissue-specific effect. However, data on the safety and effectiveness of this novel pulsed-field ablation (PFA) in octogenarians are still insufficient.

Purpose
This study aims to evaluate the procedural outcomes and complications of PFA in octogenarians with AF, in comparison to CBA, from 3 high-volume European centers.

Methods
We retrospectively enrolled patients who underwent PFA via the FarapulseTM system from January 2022 to June 2023, and those who underwent second-generation CBA from January 2015 to June 2023.

Results
A total of 176 patients (PFA group: 63, CBA group: 113) were included. The PFA group had a higher proportion of patients with persistent AF (p=0.03) and undergoing a repeat procedure (p&lt;0.01). (Table 1) Unlike CBA, PFA procedures involved additional extrapulmonary targets, such as posterior wall and mitral isthmus. Nonetheless, procedure time was similar between groups. There were no significant differences in complications but phrenic nerve palsy was not observed in the PFA group (Table 2).

Conclusions
PFA for octogenarians provides the possibility to target additional extrapulmonary sites with equivalent procedural times and safety compared to CBA, without the concern of phrenic nerve palsy.Table 1Table 2
Implementation of nurse administered propofol sedation for same-day discharge pulsed field ablation of atrial fibrillation is safe and has excellent patient reviews
Authors: Gybel C , Madsen M , Nielsen J M 
Published: May 2024

Abstract

Background
In June 2022, we introduced Pulsed Field Ablation (PFA) for de novo pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF). Simultaneously, deep sedation with propofol undertaken by trained nurses from the cath lab was introduced.

Purpose
To evaluate feasibility, safety and patient reported experience for same-day discharge AF ablations performed with PFA on propofol sedation.

Methods
Patients with an ASA physical status classification of 1 or 2 referred for de novo AF ablation were planned for PFA in propofol sedation. Three nurses with previous experience from the intensive care unit planned and undertook the sedation. In addition, two nurses were trained locally.
The initial 200 consecutive patients were included in the observational cohort study after signing consent to participate in follow-up after the procedure. Study data were collected and managed using REDCap electronic data capture tools. In addition to procedure related data, patient-reported quality measures were acquired 30 days after the procedure by an internet based questionnaire including scaling and open questions.

Results
96% of the procedures were successfully completed using only propofol while 4% were scheduled for general anesthesia, mainly because of sleep apnea and high BMI. The average procedure time for the first 100 procedures was 57 min (95% CI, 54.1-62.9) and 45 min (95% CI, 42.6-47.4) for the following 100 procedures. Acute PVI was achieved during all procedures. No sedation related adverse effects were observed. One patient experienced pericardial tamponade requiring prolonged hospitalization. 87% were discharged on the same day as planned while 12% remained hospitalized one additional day for reassurance and social reasons. 93% (186/200) completed the questionnaire. 56% of patient only responded "very little" or "not at all" to all questions about adverse symptoms during and after the procedure. For each specific symptom, 80 to 95 % were only experienced "very little" or "not at all" (Fig 1). In general, patients felt safe about the preparation for and handling of the sedation (Fig 2).

Conclusions
Nurse administered deep sedation with propofol, provides excellent pain relief for PFA procedures, facilitates an efficient workflow and can safely be implemented and administered by nurses from the cath lab. Propofol sedation constitutes an important alternative to general anesthesia that is not widely available.Figure 1Figure 2
Innovations in arrhythmia management in pregnant woman: catheter ablation without using fluoroscopy
Authors: Smagulova A , Ainabekova B , Albaev R , Abdrakhmanova Z H , Suleymen Z H , Abdrakhmanov A 
Published: May 2024

Abstract

Background
The latest data of effectiveness and safety of catheter ablation without using fluoroscopy in general population suppose wide using of this technology. However, data on pregnant population is limited.

Purpose
To investigate efficacy and safety of catheter ablation without using fluoroscopy in pregnant women with analyzing obstetric and neonatal outcomes.

Methods
We studied 47 cases of catheter ablation in pregnant (mean age 25.3±3.9 years, mean gestation age 23.7 ±3.1 weeks) within 24 month follow-up. Ablation was performed under the guidance of CARTO (n=21; 44.7%) and Ensite Precision systems (n=26; 55.3%) without using fluoroscopy in all cases.

Results
The most common arrhythmia was atrioventricular nodal reentrant tachycardia (n=21; 44.7%), which was followed by Wolff–Parkinson–White syndrome (n=15; 31.9%). Cases of combination of accessory pathways with slow conduction ways (n=3, 6.4%), ventricular tachycardia (n=3, 6.4%) and premature ventricular contraction (n=5; 10.6%) were rare. Ablation without using fluoroscopy was successful in all cases, mean procedural time was 71.9±14.5 minutes. There was one case of complication after ablation procedure: ileofemoral thrombosis, which was treated successfully without termination of gestation (2.1%). We found increased uterine contractile activity and placental abruption in pregnant after ablation in 4.54% and 2.3% cases respectively. Cases of uterine blood flow violation was more frequent: in 15.9% cases. Obstetric outcomes characterized by prevalence of vaginal delivery and delivery in term: in 76.6% and 95.7% cases. There were live births in all pregnant women with normal range of fetal birth weight and Apgar score (3207.4±485 grams and 8.4±1.6 respectively). There were no incidence of mortality and arrhythmia recurrence at follow up.

Conclusions
Catheter ablation without using fluoroscopy can be effectively and safety performed during gestation with good neonatal and obstetric outcomes.
First-time catheter ablation outcomes for atrial fibrillation are dependent on low-voltage areas rather than paroxysmal vs. persistent classifications: a REAL-AF study
Authors: Nguyen A , Pulaski M , Thorne C , Nauffal V , Osorio J , Singleton M J , Zadeh A , Zei P , Ho I , Rajendra A , Mareddy C , Lee K , Metzl M , Zaman J A B 
Published: May 2024

Abstract

Background
Left atrial low-voltage areas (LA LVA) measured at time of catheter ablation for atrial fibrillation (AF) have been increasingly recognized as an indicator of atrial fibrosis [1]. However, little is known whether first-time catheter ablation outcomes differ between paroxysmal AF (PAF) and persistent AF (PerAF) in patients with higher LA LVA, which may indicate a more advanced substrate independent of clinical subtype.

Purpose
To evaluate whether outcomes of first-time catheter ablation for AF are dependent on LA LVA rather than PAF vs. PerAF types in a multicenter registry of patients.

Methods
The Real-world Experience of Catheter Ablation for the Treatment of Symptomatic PAF and PerAF Using Novel Contact Force Technologies registry (REAL-AF) is a prospective, observational multicenter registry of patients undergoing catheter ablation. We evaluated 4181 patients undergoing first-time catheter ablation for both PAF and PerAF to determine AF recurrence within 12 months. Contact maps were created using a 5-spline high-density catheter. LA LVA was calculated using these contact maps based on a bipolar voltage of &lt;0.50 mV. LA LVA was categorized into low (&lt;5%) vs. high (≥5%) based on preliminary data. Risk of recurrence was analyzed using Cox proportional hazard models.

Results
Patients with LA LVA ≥5% who underwent first-time catheter ablation for AF (both PAF and PerAF) experienced a higher risk of AF recurrence within 12 months (Hazard ratio (HR): 1.95, p&lt;0.001), see Figure 1. Overall, 82.0% of patients were free of AF in the LA LVA &lt;5% group compared to 69.1% in the LA LVA ≥5% group. This association remained significant in a subpopulation of patients presenting in normal sinus rhythm (N = 2463) at time of ablation (HR: 1.90, p&lt;0.001). 12-month ablation outcomes between PAF and PerAF in patients with LA LVA ≥5% (N = 1590) were not statistically significant (71.0% vs 67.3% respectively, HR: 1.15, p=0.30), see Figure 2. Finally, in the LA LVA &lt;5% group (N = 2591), patients with PerAF had a 1.42 times higher risk for AF recurrence within 12 months after catheter ablation (p=0.04).

Conclusion
This is the largest real-world registry to date demonstrating that LA LVA ≥5% is associated with a higher risk of AF recurrence within 12 months in patients undergoing first-time catheter ablation for AF. Among patients with LA LVA ≥5%, AF recurrence was not associated with AF type. These findings motivate further studies into using LA LVA as a prognostic tool for patients undergoing first-time catheter ablation for AF and using non-invasive methods to assess this in order to stratify patients further.
Nationwide burden of sudden cardiac death among patients with a psychiatric disorder
Authors: Mujkanovic J , Warming P E , Winkel B G , Lynge T H , Tfelt J 
Published: May 2024

Abstract

Background and aim
Patients with psychiatric disorders have increased all-cause mortality compared to the general population. Previous research has shown that they have a 4-fold increased risk of sudden cardiac death (SCD) among the young. However, the risk across all age groups remains unknown.

Purpose
To investigate the incidence of SCD in patients with psychiatric disorders aged 18-90 years in the Danish population by systematically reviewing all deaths in one year.

Methods
We examined all deaths in Denmark among residents aged 18-90 years in 2010 by reviewing death certificates and autopsy reports. All deaths were categorized as non-SCD, or SCD, based on the available information. Psychiatric disorder was defined according to ICD-10 criteria, or by redemption of a prescription for psychotropic medication within one year prior to death.

Results
Out of 4.3 million residents in 2010 aged 18-90 years, we observed 45 703 deaths of which 6 002 were SCD. Overall, the incidence of SCD was 4.35 times (CI: 4.20-4.50, p-value &lt;0.001) higher among patients with psychiatric disorders than in the general population and was age dependent (p-value &lt;0.001). When adjusting for age, sex, and comorbidities, psychiatric disorders were independently associated with SCD, with a hazard ratio (HR) of 2.46 (2.33-2.60, p-value: &lt;0.001), with highest SCD risk among patients suffering from schizophrenic disorders with a HR of 5.27 (4.23-6.56 p-value &lt;0.001). Furthermore, patients with psychiatric disorders had an expected 10-year excess loss of life of which 13% was caused by SCD.

Conclusion
The rate of SCD in patients with psychiatric disorders was 4 times higher than in the general population. Having a psychiatric disorder is independently associated with SCD. Life-expectancy for an 18-year-old with a psychiatric disorder is projected to be 10-years shorter in comparison.Incidence rate of SCD by age groupExcess loss of life-years
Ventricular arrhythmia events in patients with implantable cardioverter-defibrillator before and after the treatment with sodium-glucose co-transporter 2 inhibitors
Authors: Giannotti Santoro M , Vecchi A , Lapira F , Puccioni E , Talini E , Menegato A , Okunuga B , Chiti C , Sardella S , Negro F , Genovesi Ebert A , Pasanisi E M G 
Published: May 2024

Abstract

Background
The role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in the treatment of chronic heart failure is expanding. However, the timing of implantable cardioverter-defibrillator (ICD) implantation for primary prevention in relation to the use of SGLT2i remains unclear. A small case series has described appropriate shocks from ICD in two patients following the initiation of SGLT2i, but a comprehensive analysis is lacking in the literature.

Methods
This study aimed to investigate the rate of ventricular arrhythmic burden and appropriate anti-tachycardia therapy from ICD before and after the initiation of SGLT2i therapy. We conducted a retrospective single-center analysis, comparing ventricular events from home monitoring reports three months before and three months after SGLT2i therapy initiation.

Results
Seventeen patients were enrolled in the study. At baseline, clinical characteristics were as follows: 13 (76%) were male, 9 (53%) had ischemic, 2 (12%) had valvular, and 6 (35%) had idiopathic cardiomyopathy. The mean end-diastolic volume (EDV) was 203 ± 90 ml, and the mean left ventricular ejection fraction was 0.36 ± 0.09. All patients were treated with beta-blockers, 14 (82%) with sacubitril-valsartan, 13 (76%) with aldosterone antagonists, 16 (94%) with furosemide, and 5 (29%) with amiodarone. SGLT2i started with dapagliflozin for 13 patients (76%), empagliflozin for 3 patients (18%), and canagliflozin for 1 patient (6%). Ten patients (59%) had single-chamber or dual-chamber ICDs, and 7 had implantable cardiac resynchronization therapy (CRT) defibrillators.
In the three months before SGLT2i treatment, 4/17 patients had non-sustained ventricular tachycardia (NSVT), compared to 8/17 (23% vs. 47%, p-value 0.23) patients with NSVT after treatment. Seven patients (41%) experienced an increase in the rate of NSVT events, with one patient having 28 NSVT events after treatment versus none before treatment. No patients had anti-tachycardia therapy in the three months before treatment, while in the three months after SGLT2i treatment, 1 patient had ventricular tachycardia treated with anti-tachycardia pacing (110 days after the beginning of the treatment), and 2 patients had ventricular tachycardia treated with appropriate shocks (2 and 25 days after the initiation of SGLT2i treatment).

Conclusion
This small retrospective analysis revealed an increase in ventricular arrhythmic events in the three months following the initiation of SGLT2i. These findings highlight the need for a more extensive analysis to establish a stronger statistical correlation.
Socioeconomic inequalities in the uptake of postpartum care at home across Dutch neighbourhoods
Authors: Daalderop Leonie A , de Vries Eline F , Steegers Eric A P , Been Jasper V , Struijs Jeroen N , Lagendijk Jacqueline 
Published: May 2024

Abstract

Background
Postpartum care focuses on prevention of health problems by performing medical check-ups and through enhancing maternal empowerment, the parent–infant interaction and knowledge about mother’s own health and that of her newborn. We aimed to investigate whether there was significant clustering within neighbourhoods regarding the uptake of postpartum care and to what extent neighbourhood-level differences are explained by individual socio-demographic factors, pregnancy-related factors and neighbourhood-level determinants (i.e. deprivation and urbanization).

Methods
A nationwide population-based observational study was carried out using linked routinely collected healthcare data from appropriate-for-gestational-age weight live-born term singleton deliveries (2015–18) in the Netherlands. We performed two-level multivariable logistic regression analyses, using three different models. Model 1 contained no explanatory variables and was used to assess clustering of postpartum care uptake within neighbourhoods. In model 2, individual-level determinants were added one by one and in model 3, neighbourhood-level determinants were added.

Results
About 520 818 births were included. Multilevel modelling showed that 11% of the total variance in postpartum care uptake could be attributed to the neighbourhood of residence. Individual characteristics explained 38% of the neighbourhood variance, of which income and migration background were the most important contributors. An additional 6% of the variation could be explained by neighbourhood-level determinants.

Conclusion
We found substantial neighbourhood differences in postpartum care uptake. These differences are influenced by a complex interplay between individual-level and neighbourhood-level determinants, highlighting the importance of addressing both individual and neighbourhood-level determinants to improve the uptake of postpartum care and therewith overall community health.